Dimension gets $500M to bankroll biotech’s convergence with tech

BioPharma Dive December 9, 2024
Ben Fidler

The firm’s co-founders claim to be pursuing a “contrarian” approach, building a team equally versed in both computing and life sciences.

Dive Brief:

Dimension, a young biotech venture firm run by former Lux Capital and Obvious Ventures investors, has raised its second fund in two years.
Called Dimension II, the $500 million fund announced Monday surpasses the $350 million the firm debuted with in January 2023. Like the earlier fund, Dimension II will support companies working at the “interfaces of life science and technology,” its three co-founders and managing partners wrote in a blog post. It’s investing in tech-powered therapeutics companies as well as developers of tools and manufacturing techniques that aid in drugmaking and discovery.
In an interview,...

Today's Sponsors

2024-12-09T14:51:13-05:00